Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxici...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Sakamuri, Divya, Glitza, Isabella C., Betancourt Cuellar, Sonia L., Subbiah, Vivek, Fu, Siqing, Tsimberidou, Apostolia M., Wheler, Jennifer J., Hong, David S., Naing, Aung, Falchook, Gerald S., Fanale, Michelle A., Cabanillas, Maria E., Janku, Filip
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935561/
https://ncbi.nlm.nih.gov/pubmed/29237802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0673
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares